Immunoscintigraphy

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Immunoscintigraphy is a nuclear medicine procedure used to find cancer cells in the body by injecting a radioactively labeled antibody, which binds predominantly to cancer cells and then scanning for concentrations of radioactive emissions.[1][2]

Clinical applications[edit]

Immunoscintigraphy is performed using a variety of radiopharmaceuticals, for a large range of purposes. Colorectal cancer is one of the most studied areas, with 111In or 99mTc labelled epitopes of the carcinoembryonic antigen.[3] The antibody capromab pendetide reacts with prostate membrane specific antigen (PMSA) and can be labelled with Indium-111.[4]

See also[edit]

References[edit]

  1. ^ "Imaging Techniques for the Diagnosis of Ovarian Cancers: Immunoscintigraphy". 21 December 2004. 
  2. ^ "Immunoscintigraphy". NCI Dictionary of Cancer Terms. National Cancer Institute. Retrieved 1 June 2017. 
  3. ^ Matzku, Siegfried; Stahel, Rolf A (1999). Antibodies in Diagnosis and Therapy. CRC Press. p. 143. ISBN 9789057023101. 
  4. ^ Fass, Leonard (August 2008). "Imaging and cancer: A review". Molecular Oncology. 2 (2): 115–152. doi:10.1016/j.molonc.2008.04.001Freely accessible. PMID 19383333.